JP2005530736A5 - - Google Patents

Info

Publication number

JP2005530736A5

JP2005530736A5 JP2003585730A JP2003585730A JP2005530736A5 JP 2005530736 A5 JP2005530736 A5 JP 2005530736A5 JP 2003585730 A JP2003585730 A JP 2003585730A JP 2003585730 A JP2003585730 A JP 2003585730A JP 2005530736 A5 JP2005530736 A5 JP 2005530736A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

optionally substituted

amount

beta blocker

esmolol

Prior art date

2003-04-18

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 29
• 239000002876 beta blocker Substances 0.000 claims 17
• 229940097320 beta blocking agent Drugs 0.000 claims 17
• AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 claims 12
• 229960003745 esmolol Drugs 0.000 claims 12
• -1 3-tetrahydrothiofuranyl Chemical group 0.000 claims 10
• 239000000203 mixture Substances 0.000 claims 9
• 150000001875 compounds Chemical class 0.000 claims 8
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims 8
• OESBDSFYJMDRJY-BAYCTPFLSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[[(3r)-oxolan-3-yl]amino]purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N[C@H]3COCC3)=C2N=C1 OESBDSFYJMDRJY-BAYCTPFLSA-N 0.000 claims 6
• 229910052739 hydrogen Inorganic materials 0.000 claims 6
• 239000001257 hydrogen Substances 0.000 claims 6
• IZRXENCTXNMAMI-DIJFLQFKSA-N (2s,3s,4r,5r)-2-[(2-fluorophenyl)sulfanylmethyl]-5-[6-[[(1r,2r)-2-hydroxycyclopentyl]amino]purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1CCC[C@H]1NC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CSC=2C(=CC=CC=2)F)O1 IZRXENCTXNMAMI-DIJFLQFKSA-N 0.000 claims 5
• 229940122614 Adenosine receptor agonist Drugs 0.000 claims 5
• 239000003379 purinergic P1 receptor agonist Substances 0.000 claims 5
• 125000002252 acyl group Chemical group 0.000 claims 4
• 125000001072 heteroaryl group Chemical group 0.000 claims 4
• 125000000623 heterocyclic group Chemical group 0.000 claims 4
• 229960003712 propranolol Drugs 0.000 claims 4
• 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
• METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical group CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
• 229960002274 atenolol Drugs 0.000 claims 3
• 150000002431 hydrogen Chemical class 0.000 claims 3
• ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 claims 3
• 229960002370 sotalol Drugs 0.000 claims 3
• 125000000547 substituted alkyl group Chemical group 0.000 claims 3
• 125000003107 substituted aryl group Chemical group 0.000 claims 3
• 101150007969 ADORA1 gene Proteins 0.000 claims 2
• 125000002947 alkylene group Chemical group 0.000 claims 2
• 125000004093 cyano group Chemical group *C#N 0.000 claims 2
• 125000001475 halogen functional group Chemical group 0.000 claims 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims 2
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
• IZRXENCTXNMAMI-NIKQVSCUSA-N (2s,3s,4r)-2-[(2-fluorophenyl)sulfanylmethyl]-5-[6-[[(1r,2r)-2-hydroxycyclopentyl]amino]purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1CCC[C@H]1NC1=NC=NC2=C1N=CN2C1[C@H](O)[C@H](O)[C@@H](CSC=2C(=CC=CC=2)F)O1 IZRXENCTXNMAMI-NIKQVSCUSA-N 0.000 claims 1
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
• 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
• 241000124008 Mammalia Species 0.000 claims 1
• 125000000217 alkyl group Chemical group 0.000 claims 1
• 206010003119 arrhythmia Diseases 0.000 claims 1
• 230000006793 arrhythmia Effects 0.000 claims 1
• 239000000480 calcium channel blocker Substances 0.000 claims 1
• 229940097217 cardiac glycoside Drugs 0.000 claims 1
• 239000002368 cardiac glycoside Substances 0.000 claims 1
• 150000002009 diols Chemical class 0.000 claims 1
• 125000001207 fluorophenyl group Chemical group 0.000 claims 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
• MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 claims 1
• LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
• 125000004545 purin-9-yl group Chemical group N1=CN=C2N(C=NC2=C1)* 0.000 claims 1
• 229930002534 steroid glycoside Natural products 0.000 claims 1
• 239000000126 substance Substances 0.000 claims 1
• 0 *c1c2nc[n](C([C@@]3O)O[C@@](CO)[C@@]3O)c2ncn1 Chemical compound *c1c2nc[n](C([C@@]3O)O[C@@](CO)[C@@]3O)c2ncn1 0.000 description 3